Addyi and Hormonal Contraceptives: Is the Combination Safe?

How Flibanserin Works and Why CYP3A4 Matters

Flibanserin is a postsynaptic 5-HT1A receptor agonist and 5-HT2A receptor antagonist approved by the FDA in 2015 for acquired, generalized HSDD in premenopausal women [1]. It modulates serotonin and dopamine signaling in the prefrontal cortex rather than acting on hormonal pathways. This distinction matters. Because flibanserin does not alter estrogen, progesterone, or gonadotropin levels, its pharmacodynamic profile does not overlap with hormonal contraceptives [2].

The drug undergoes extensive hepatic metabolism. CYP3A4 accounts for the majority of flibanserin biotransformation, with CYP2C19 playing a secondary role [1]. Peak plasma concentration occurs approximately 0.75 hours after oral dosing, and the elimination half-life averages 11 hours in the fed state. Any co-administered drug that meaningfully inhibits or induces CYP3A4 can shift flibanserin exposure, which is why the FDA label includes specific contraindications for strong CYP3A4 inhibitors such as ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, and certain HIV protease inhibitors [1]. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice) also require avoidance or careful management [3].

Hormonal contraceptives do not fall into either of those categories.

The FDA Pharmacokinetic Study: What the Data Show

The Addyi prescribing information describes a dedicated drug-drug interaction study evaluating co-administration with a combined oral contraceptive containing ethinyl estradiol 0.035 mg and norethindrone 1 mg [1]. This study measured the effect of the oral contraceptive on flibanserin plasma concentrations and vice versa.

Results were straightforward. Co-administration produced no clinically meaningful change in flibanserin AUC or Cmax [1]. The oral contraceptive did not raise flibanserin exposure to a degree that would warrant dose reduction or additional monitoring. Ethinyl estradiol is classified as a weak CYP3A4 inhibitor [4]. Weak inhibitors typically increase the AUC of a CYP3A4 substrate by <2-fold, a threshold below the level associated with the hypotension and syncope risk that triggered flibanserin's boxed warning [1].

The reverse direction was equally reassuring. Flibanserin did not reduce the plasma levels of ethinyl estradiol or norethindrone, meaning contraceptive efficacy remains intact [1]. This is clinically significant for the target population: premenopausal women who may rely on hormonal contraception while being treated for HSDD.

A 2016 pooled analysis of the three key phase III trials (BEGONIA, DAISY, and VIOLET; combined N = 2,997) confirmed that the most common adverse events with flibanserin 100 mg at bedtime were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%) [5]. The analysis did not identify hormonal contraceptive use as a modifier of adverse event frequency or severity.

Why Hormonal Contraceptives Are Not a Risk With Addyi

Drug interaction risk depends on three dimensions: mechanism, magnitude, and clinical consequence. For the flibanserin plus hormonal contraceptive combination, all three dimensions indicate low risk.

Mechanism. Ethinyl estradiol weakly inhibits CYP3A4 [4]. Progestins used in combined and progestin-only formulations (norethindrone, levonorgestrel, desogestrel, drospirenone, etonogestrel) show minimal CYP3A4 inhibitory activity at therapeutic concentrations [6]. Neither component of a typical hormonal contraceptive acts as a moderate or strong CYP3A4 inhibitor.

Magnitude. The FDA interaction study demonstrated that the change in flibanserin exposure with concurrent oral contraceptive use was below the threshold of clinical significance [1]. Compare this to ketoconazole (a strong CYP3A4 inhibitor), which increased flibanserin AUC by approximately 4.5-fold. That magnitude of increase is what triggers dangerous hypotension [1].

Clinical consequence. The adverse event profile in women taking both flibanserin and hormonal contraceptives across clinical trials did not differ from women taking flibanserin alone [5]. No signal for increased syncope, hypotension, or sedation emerged from the combined population data.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges flibanserin as a treatment option for premenopausal HSDD and does not list hormonal contraceptives among agents requiring special precaution during flibanserin therapy [7].

Drug Interactions That Actually Warrant Concern With Flibanserin

While hormonal contraceptives are safe to combine with Addyi, several other interaction categories are not. Clinicians and patients should focus monitoring efforts on these established risks.

Strong CYP3A4 inhibitors are contraindicated. The FDA label carries a boxed warning: concurrent use of flibanserin with strong CYP3A4 inhibitors increases flibanserin exposure to levels that cause severe hypotension and syncope [1]. Ketoconazole increased flibanserin AUC 4.5-fold; fluconazole (a moderate inhibitor) increased it 7-fold due to additional CYP2C19 inhibition [1]. Both are contraindicated.

Alcohol is the highest-profile risk. In a pharmacodynamic interaction study, flibanserin plus alcohol (0.4 g/kg in women, 0.6 g/kg in men) caused significant reductions in systolic blood pressure and increased rates of hypotension, syncope, and sedation compared to either agent alone [8]. The FDA requires a REMS (Risk Evaluation and Mitigation Strategy) program specifically because of this interaction [1]. Patients must abstain from alcohol while taking Addyi.

Moderate CYP3A4 inhibitors require a washout. If a patient has been taking a moderate CYP3A4 inhibitor, the Addyi label recommends waiting 2 weeks after discontinuation of the inhibitor before initiating flibanserin [1]. Common moderate inhibitors include erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, and grapefruit juice.

CYP3A4 inducers reduce efficacy. Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort accelerate flibanserin metabolism and may reduce its therapeutic effect [1]. Co-administration is not recommended.

"Prescribers should perform a thorough medication reconciliation before initiating flibanserin, with particular attention to antifungals, macrolide antibiotics, and HIV medications," according to the 2015 FDA Drug Safety Communication accompanying the Addyi approval [9].

Which Contraceptive Methods Are Compatible With Addyi

All currently marketed hormonal contraceptive formulations are compatible with flibanserin based on pharmacokinetic and pharmacodynamic data.

Combined oral contraceptives (COCs). The FDA label's interaction study used a COC containing ethinyl estradiol 0.035 mg / norethindrone 1 mg and found no interaction [1]. COCs with other progestins (levonorgestrel, norgestimate, drospirenone, desogestrel) share the same weak or negligible CYP3A4 inhibition profile [6].

Progestin-only pills. Norethindrone 0.35 mg (the "minipill") does not meaningfully inhibit CYP3A4 [6]. No interaction is expected.

Long-acting reversible contraception (LARC). Hormonal IUDs (levonorgestrel-releasing, e.g., Mirena, Liletta) deliver progestin locally with minimal systemic absorption [10]. The etonogestrel implant (Nexplanon) achieves low systemic progestin levels. Neither method presents a CYP3A4 interaction concern.

Injectable and patch/ring. Depot medroxyprogesterone acetate (Depo-Provera) is not a CYP3A4 inhibitor. The norelgestromin/ethinyl estradiol patch (Xulane) and the etonogestrel/ethinyl estradiol vaginal ring (NuvaRing) deliver ethinyl estradiol transdermally or vaginally at systemic levels comparable to or lower than oral COCs [6].

Non-hormonal methods (copper IUD, barrier methods) have no pharmacokinetic interaction potential with any oral medication, making them a moot point from a drug interaction perspective.

Monitoring and Patient Counseling Recommendations

No special monitoring is required when a patient takes flibanserin and a hormonal contraceptive simultaneously. Standard Addyi counseling should cover the following points.

Take flibanserin 100 mg at bedtime. Bedtime dosing minimizes the risk of hypotension, dizziness, and somnolence during waking hours [1]. Patients should not take the dose if they cannot commit to a full night of sleep.

Avoid alcohol completely. This is the single most important safety message. Even small amounts of alcohol can precipitate dangerous drops in blood pressure when combined with flibanserin [8].

"Patients should be advised that they must not consume alcohol while taking Addyi, as the combination increases the risk of severe hypotension and loss of consciousness," states the Addyi REMS prescriber training material [1].

Report new medications to the prescriber. Any newly prescribed antifungal, antibiotic, HIV medication, or herbal supplement could change flibanserin exposure via CYP3A4. Patients should notify their healthcare provider before starting any new medication [1].

Assess response at 8 weeks. The FDA label recommends discontinuing flibanserin if no improvement in sexual desire occurs after 8 weeks [1]. Continuing an ineffective medication exposes the patient to risk without benefit.

Specific Populations: CYP2C19 Poor Metabolizers and Hepatic Impairment

Two pharmacogenomic and physiologic variables affect flibanserin exposure more than any hormonal contraceptive could.

CYP2C19 poor metabolizers (approximately 2% of Caucasians, 15% of East Asians) show higher flibanserin exposure because the minor metabolic pathway is impaired [1][11]. The FDA label notes this but does not mandate CYP2C19 genotyping before prescribing. Clinicians should be aware that poor metabolizers may experience more pronounced sedation or dizziness.

Hepatic impairment is a contraindication. Flibanserin exposure increased 4.5-fold in patients with moderate hepatic impairment (Child-Pugh B) [1]. Because the drug is contraindicated in any degree of hepatic impairment, liver function should be assessed before initiation.

Neither of these risk factors is worsened by hormonal contraceptive co-administration. A CYP2C19 poor metabolizer taking a COC will not experience additional flibanserin accumulation beyond what the genotype alone produces [1].

The REMS Program and Prescriber Certification

Flibanserin is available only through the Addyi REMS program. Prescribers must complete a training module and enroll in the program before writing prescriptions [1]. Pharmacies must also be certified. The REMS exists because of the alcohol and CYP3A4 inhibitor interactions, not because of any hormonal contraceptive risk.

As of 2024, the FDA reported that over 18,000 healthcare providers had enrolled in the REMS program since Addyi's 2015 approval [9]. The REMS patient agreement requires the patient to confirm understanding of the alcohol prohibition and the CYP3A4 inhibitor risk. Hormonal contraceptive use does not require disclosure under the REMS agreement.